Ronald Asbury Andrews Oncocyte Corp (OCX) insider trading activity

Ronald Asbury Andrews is Former CEO of Oncocyte Corp. Currently has a direct ownership of 583,212 shares of OCX, which is worth approximately $1.28 Million. The most recent transaction as insider was on Dec 01, 2022, when has been sold 250,000 shares (Common Stock, No Par Value) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 583K

0% 3M change

0% 12M change

Total Value Held $1.28 Million

RONALD ASBURY ANDREWS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2022	BUY Exercise of conversion of derivative security	-	250,000 Added 30.0%	583,212 Common Stock, No Par V...
Aug 16 2022	BUY Open market or private purchase	$38,400 $0.96 p/Share	40,000 Added 10.72%	333,212 Common Stock, No Par V...
Mar 16 2022	BUY Open market or private purchase	$64,000 $1.28 p/Share	50,000 Added 14.57%	293,212 Common Stock, No Par V...
Jul 01 2021	SELL Payment of exercise price or tax liability	-	15,834 Reduced 6.11%	243,212 Common Stock, No Par V...
Jul 01 2021	BUY Exercise of conversion of derivative security	-	65,000 Added 20.06%	259,046 Common Stock, No Par V...
Jun 30 2021	SELL Payment of exercise price or tax liability	-	25,873 Reduced 11.76%	194,046 Common Stock, No Par V...
May 07 2021	BUY Exercise of conversion of derivative security	-	106,221 Added 32.57%	219,919 Common Stock, No Par V...
Mar 19 2021	BUY Open market or private purchase	$52,690 $4.79 p/Share	11,000 Added 8.82%	113,698 Common Stock, No Par V...

Also insider at

PRPO

Precipio, Inc. Healthcare

Director

RAA